Michael McCaughan
When Big Pharma executives looked at House Speaker Nancy Pelosi’s agenda for 2007, they didn’t see this coming.
With Enemies Like These: Will the Democrats Make Part D More Pharma Friendly?
The Democratic leadership rammed a major health bill through the House this summer, including some Medicare Part D fixes that read like a Big Pharma wish list. Have the industry's toughest critics gone soft?
More from Market Access
More from Pink Sheet
• By
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
• By
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
• By
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.